The Medical journal of Australia
The most recent articles from:
Med. J. Aust.
-
Clinical Trial
Lumbar myelography today. Experience with metrizamide, a water-soluble, non-ionic contrast medium.
A clinical assessment of metrizamide (Amipaque) lumbar myelography in 150 patients is reported, and the adverse reactions encountered are presented and discussed. Minor adverse reactions--headache (48%), nausea (10%) and vomiting (7%)--were common, and the incidence reflected overseas experience. ⋯ The study suggests that metrizamide is well tolerated, gives good anatomical demonstration and should replace iophendylate (Myodil) in this region. Recent reports of occasional, but sometimes severe, neurological complications indicate that further cautious assessment is required.